Fierce Biotech’s Quarterly IPO and M&A Roundup: Q1’24

The award for the biggest M&A deal of the first quarter of 2024 goes to Gilead Sciences, which acquired CymaBay Therapeutics for $4.43 billion in February, according to a review of data from market intelligence platform S&P Capital IQ. Following Gilead was Novartis’ $2.77 billion buyout of cancer specialist MorphoSys, then AstraZeneca’s $2.41 billion outlay for Fusion Pharmaceuticals. All three of these deals spoke to the Big Pharma trend of snapping up small-bite biotechs with a late-stage tilt.

Read the full article: Fierce Biotech’s Quarterly IPO and M&A Roundup: Q1’24 //

Source: https://www.fiercebiotech.com/biotech/fierce-biotechs-quarterly-ipo-and-ma-roundup-q124

Leave a Comment

Your email address will not be published.

Scroll to Top